Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,602 recruiting studies in this area right now.
By phase
- Not applicable9,790
- Phase 24,449
- Phase 12,736
- Phase 1/Phase 21,687
- Phase 31,397
- Phase 2/Phase 3280
- Phase 4263
Top conditions
- Breast Cancer1,227
- Cancer661
- Prostate Cancer654
- Colorectal Cancer491
- Lung Cancer424
- Ovarian Cancer338
- Multiple Myeloma332
- Gastric Cancer296
- Acute Myeloid Leukemia292
- Pancreatic Cancer290
- Hepatocellular Carcinoma283
- Solid Tumor257
- Advanced Solid Tumor255
- Cervical Cancer232
- Head and Neck Cancer227
- Endometrial Cancer206
- Advanced Solid Tumors193
- Esophageal Cancer191
Leading sponsors
- M.D. Anderson Cancer Center450
- Fudan University313
- Sun Yat-sen University290
- Memorial Sloan Kettering Cancer Center288
- National Cancer Institute (NCI)285
- Mayo Clinic240
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences151
- City of Hope Medical Center147
- AstraZeneca134
- University Health Network, Toronto125
Where studies are running
- California1,424
- Texas638
- Arizona513
- Florida448
- Alabama420
- New York409
- Massachusetts343
- Maryland329
- New Jersey269
- Pennsylvania241
Recruiting studies20,602 total
- NCT07237230Recruiting
Gamma-delta T cells to prevent leukemia relapse after transplant
This trial tests if a special type of immune cell called gamma-delta T cells can help prevent acute myeloid leukemia from coming back after a stem cell transplant. It is for people with high-risk features who have recently had a transplant.
Wuhan, HubeiAges 18–65 - NCT07607678RecruitingPhase 1
Testing BI 3819026 Alone and With Ezabenlimab for Advanced Cancer
This early-stage study tests whether a new drug called BI 3819026, alone or combined with another drug called ezabenlimab, is safe and well-tolerated in people whose advanced solid tumors have stopped responding to standard treatments. The goal is to find the right dose and understand how the drugs work in your body.
New Haven, ConnecticutAges 18 years+ - NCT06698692Recruiting
Preventing low blood counts with trilaciclib after chemoradiation for esophageal cancer
This trial tests an investigational drug called trilaciclib that is given before chemoradiation to help protect your bone marrow and reduce side effects like low blood counts. It is for people with a specific type of esophageal cancer who have finished their main treatment.
Nanjing, JiangsuAges 18 years+ - NCT07235371Recruiting
Electrical Acupoint Stimulation for Bladder Recovery After Cervical Cancer Surgery
This study tests whether a gentle, non-invasive electrical stimulation on specific acupoints (like acupuncture points) can help you regain bladder control after cervical cancer surgery. If you've had a catheter for a few weeks and haven't been able to pee on your own, this might be an option to help retrain your bladder.
Hangzhou, ZhejiangAges 18–70 - NCT06128018Recruiting
Endoscopic vs surgical bypass for stomach blockage
This study compares two ways to help with gastric outlet obstruction (a blockage in the stomach or small intestine) caused by a tumor. It tests if a procedure using an endoscope (a long, flexible tube with a camera) is as good as surgery to help you eat and drink more comfortably.
Orlando, FloridaAges 18 years+ - NCT05916261RecruitingEarly Phase 1
Personalized pancreatic cancer vaccines with pembrolizumab
This early-phase trial tests a personalized cancer vaccine made from your tumor, along with pembrolizumab, to help the immune system attack advanced pancreatic cancer. It may be an option if your cancer has specific immune “targets” and if you meet several health, lab, and infection requirements.
Qionghai, HainanAges 18 years+ - NCT06754059Recruiting
Pyrotinib with trastuzumab for HER2-positive breast cancer maintenance
This trial tests a combination of two targeted drugs (pyrotinib and trastuzumab) as maintenance therapy to keep HER2-positive breast cancer that has spread under control. It is for women who have already received some first-line treatment and are stable enough to continue therapy.
Fuzhou, FujianAges 18–70 - NCT07604064RecruitingPhase 2
IDH1 Inhibitor Treatment for Relapsed or Refractory Blood Cancer
This trial tests a drug called olutasidenib in Japanese patients with acute myeloid leukemia (a serious blood cancer) that has come back or stopped responding to previous treatment. The drug targets a specific genetic change (IDH1 mutation) that some leukemia cells have, and may help patients whose cancer is difficult to treat.
Tokyo and Other Japanese CitiesAges 18 years+ - NCT06060405RecruitingPhase 2
Immunotherapy before surgery for pancreatic cancer
This trial tests a combination of two immunotherapy drugs (durvalumab and oleclumab) given before surgery to people with pancreatic cancer that can be removed. The goal is to see if this treatment helps the immune system fight the cancer better.
Toronto, OntarioAges 18 years+ - NCT06288191RecruitingPhase 2
Nivolumab and relatlimab before surgery for skin cancer
This trial tests if two immunotherapy drugs, nivolumab and relatlimab, given before surgery can help shrink a type of skin cancer called cutaneous squamous cell carcinoma. It's for people whose cancer can be removed with surgery.
Wollstonecraft, New South WalesAges 18 years+ - NCT06715384Recruiting
Testing a new camera tool to measure colon polyps
This trial tests a computer-assisted measurement system during a colonoscopy to see if it can more accurately measure polyps. You might consider this if you are scheduled for a routine colonoscopy for screening or monitoring.
Shanghai, Shanghai MunicipalityAges 18–85 - NCT07234110Recruiting
CD5 CAR-T therapy for returning blood cancers
This trial tests a new treatment using your own immune cells, modified to find and attack cancer cells that have a CD5 marker. It may be an option for people with certain lymphomas or leukemia that have not responded to standard treatments or have come back.
Tianjin, Tianjin MunicipalityAges 1–70 - NCT06752681RecruitingPhase 1
Testing day301 for advanced solid tumors
This trial tests a new drug called DAY301 for people with certain advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and if it can shrink tumors.
New Haven, ConnecticutAges 18 years+ - NCT06208917RecruitingPhase 3
Comparing two ways to give ondansetron for chemo nausea in kids
This trial compares two forms of ondansetron (a nausea medicine) — a dissolving film you put in the mouth versus a needle injection — to see which works better in preventing nausea and vomiting caused by chemotherapy in children with solid tumors.
Guangzhou, GuangdongAges 6 months–18 years - NCT07229638RecruitingPhase 1/Phase 2
Study of SHR-9839 with other treatments for solid tumors
This study tests a new drug called SHR-9839 given under the skin, combined with other anti-cancer treatments, for people with solid tumors. The goal is to see if it is safe and effective.
Nanjing, JiangsuAges 18–70 - NCT06228209Recruiting
Palliative care for advanced heart failure or cancer
This study tests whether adding a palliative care specialist to your regular care team can improve your quality of life if you have advanced heart failure or advanced lung or certain gastrointestinal cancers. It is for people who have been in the hospital recently and live in Manhattan.
New York, New YorkAges 18 years+ - NCT06304571RecruitingPhase 1
Study of HC006 for advanced solid tumors
This study tests a new drug called HC006 for advanced solid tumors that no longer respond to standard treatments. It aims to find a safe dose and see if it helps shrink tumors.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06751849RecruitingPhase 2
Vaccine, immunotherapy, and radiation for advanced lung cancer
This trial tests a combination of a personalized cancer vaccine, an immunotherapy drug (PD-1 inhibitor), and radiation therapy for people with advanced non-small cell lung cancer that has gotten worse after at least two prior treatments. The goal is to see if this approach can help shrink tumors or slow cancer growth.
Nanchang, JiangxiAges 18–70 - NCT06687070RecruitingPhase 1
APG-2449 alone or with PLD for advanced cancers
This trial tests a new drug, APG-2449, either alone or with another chemotherapy called PLD (pegylated liposomal doxorubicin). It is for people with advanced solid tumors, including ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if the drug can shrink tumors and how safe it is.
Guangzhou, GuangdongAges 18 years+ - NCT07368478RecruitingPhase 1
Study of BC2027 for advanced solid tumors with GPC3
This trial tests a new drug called BC2027 for people with advanced solid tumors that have a protein called GPC3. If standard treatments have stopped working, are not available, or caused side effects, this study may offer a new option.
Shanghai, Shanghai, ChinaAges 18 years+ - NCT05039073RecruitingPhase 2
Brentuximab plus nivolumab for Hodgkin lymphoma after prior treatment
This Phase 2 study tests brentuximab and nivolumab (two anti-cancer medicines) in people with classical Hodgkin lymphoma that has come back or did not respond to earlier treatment. It may help by attacking lymphoma cells in different ways, especially after limited options from prior therapies.
Atlanta, GeorgiaAges 12 years+ - NCT06702566Recruiting
Study of Ferritin in Immune-Related Side Effects
This study looks at how a blood marker called ferritin relates to side effects from immunotherapy or other cancer treatments. It may help doctors predict and manage those side effects better.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07222761RecruitingPhase 3
Comparing new treatments for relapsed multiple myeloma
This trial tests if a new medicine called linvoseltamab, alone or combined with carfilzomib, works better than the usual treatments for people with multiple myeloma that has come back or stopped responding after 1 to 3 prior therapies.
Atlanta, GeorgiaAges 18 years+ - NCT06254248RecruitingPhase 2
Safety of two cancer drugs after liver transplant
This trial tests a combination of two drugs (atezolizumab and bevacizumab) for people whose liver cancer has returned after a liver transplant and cannot be treated with surgery or other local procedures. The goal is to see if this treatment is safe for liver transplant recipients.
ClichyAges 18–90
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,602 recruiting oncology studies from the U.S. registry right now, out of 31,289 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.